Nowadays, therapeutic blockade of the immune checkpoint programmed cell death receptor 1 (PD-1) alone or in combination with targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is standard-of-care treatment for metastatic melanoma. Here, CTLA4 is linked to metastatic melanoma.